Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The McKesson Corporation (NYSE: MCK) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about McKesson’s healthcare services and pharmaceutical distribution activities, capital structure, governance, and financial reporting.
McKesson’s common stock and several series of notes, including 1.500% Notes due 2025, 1.625% Notes due 2026, and 3.125% Notes due 2029, are listed on the New York Stock Exchange, as shown in multiple Form 8-K filings. Filings such as Form 8-K report material events, including preliminary quarterly results, updated fiscal guidance, changes to reportable segments, and investor events like Investor Day. A Form 25 filing for 1.500% Notes due 2025 illustrates how specific debt securities can be removed from listing and registration on an exchange.
Investors can also review proxy materials, such as the definitive proxy statement (DEF 14A), which describes McKesson’s purpose, values, Board oversight, compensation matters, and shareholder voting results. These documents provide context on corporate governance, culture, and strategic priorities, including the company’s focus on North American pharmaceutical distribution, oncology and biopharma services platforms, and portfolio modernization.
On Stock Titan, SEC filings for MCK are updated from EDGAR and presented with AI-powered summaries designed to clarify key points in lengthy documents. Users can quickly identify the nature of each filing, from current reports on Form 8-K to proxy statements and other disclosures, and use AI-generated insights to understand segment changes, capital allocation decisions, and governance topics without reading every line of the underlying text.
This page is a useful starting point for reviewing McKesson’s regulatory history, tracking material events, and examining how the company communicates financial and strategic information through its SEC submissions.
Form 144 notice for McKesson Corporation (MCK) shows an intended sale of 11,930 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $8,418,165.90 and an approximate sale date of 08/22/2025. The shares reported for sale were acquired via restricted stock vesting in three tranches: 9,930 shares on 05/20/2025, 1,333 shares on 05/21/2025 and 667 shares on 05/23/2025; consideration is listed as compensation. The filing discloses prior sales by the same person in the past three months: 19,370 shares on 06/06/2025 for $13,673,864.10, 19,371 shares on 07/11/2025 for $13,716,411.39 and 11,930 shares on 08/15/2025 for $8,085,676.80. The seller is named as Brian S. Tyler with an address shown. The form includes the required attestation that the seller does not possess undisclosed material adverse information.
Tyler Brian S., who is listed as Chief Executive Officer and a director of McKesson Corporation (MCK), reported a sale of 11,930 shares of McKesson common stock on 08/15/2025 at a price of $677.76 per share. After the reported transaction he beneficially owned 15,942 shares directly and 215.2803 shares indirectly through the McKesson Corporation 401(k) Retirement Savings Plan.
The filing indicates the sale was made pursuant to a previously adopted plan dated November 8, 2024 and the form was signed by an attorney-in-fact on 08/19/2025. The report includes the reporting persons address in Irving, Texas, and the document is a Section 16 Form 4 disclosure of changes in beneficial ownership.
Form 144 filed for McKesson Corporation (MCK) documents a proposed sale of 11,930 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $8,085,676.80. The 11,930 shares were all acquired as restricted stock vesting on 05/20/2025 (9,930 shares), 05/23/2025 (667 shares), and 05/24/2025 (1,333 shares) as compensation. The notice shows an approximate sale date of 08/15/2025 and names Fidelity Brokerage Services LLC as the broker. The filing also reports insider sales during the past three months by Brian S. Tyler totaling 38,741 shares sold on 06/06/2025 and 07/11/2025 for combined gross proceeds of $27,390,275.49. The form includes the required representation that the seller does not possess undisclosed material adverse information.
Rutledge Napoleon B. Jr., SVP, Controller & CAO of McKesson Corporation (MCK), reported a sale of common stock under a pre-existing Rule 10b5-1 trading plan. The filing shows a transaction on 08/08/2025 in which 329 shares were sold at $663.67 per share, leaving the reporting person with 657 shares held directly. The form indicates the sale was executed pursuant to a plan adopted February 7, 2025, and the form was signed by an attorney-in-fact on 08/11/2025. The filing contains only this single non-derivative sale disclosure and does not provide additional company financial information.
McKesson Corporation (MCK) filed a Current Report on Form 8-K dated August 6, 2025. The Company states it furnished its preliminary results for the quarter ended June 30, 2025, which are attached as Exhibit 99.1 (earnings release). The filing clarifies that the information, including Exhibit 99.1, is furnished to the SEC and shall not be deemed "filed" under Section 18 of the Exchange Act or incorporated by reference except by specific reference.
Key filing details:
- Report date: August 6, 2025
- Exhibits filed: 99.1 (earnings release) and 104 (iXBRL cover page)
- Signed by: Britt J. Vitalone, Executive Vice President and Chief Financial Officer
- Securities listed on NYSE: Common stock (MCK), 1.500% Notes due 2025 (MCK25), 1.625% Notes due 2026 (MCK26), 3.125% Notes due 2029 (MCK29)
McKesson Corporation (NYSE: MCK) filed an 8-K summarizing the 30 July 2025 Annual Meeting results (Item 5.07).
- All 12 director nominees were re-elected; support exceeded 95% of votes cast, with only ~0.9-4.7 m "against" votes and 10.3 m broker non-votes per nominee.
- Shareholders ratified Deloitte & Touche LLP as independent auditor for FY 2026 by a 92% majority (102.2 m for / 8.6 m against / 0.1 m abstain).
- The advisory say-on-pay proposal also passed with ~92% approval (91.8 m for / 8.0 m against / 0.8 m abstain).
No additional business, strategic announcements or financial guidance were disclosed. The outcome signals continued investor confidence in board composition, executive pay and audit oversight but carries limited immediate valuation impact.